

ACCESS TO COVID-19 TOOLS (ACT) ACCELERATOR

24 April 2020

A Global Collaboration to Accelerate the Development, Production and Equitable Access to New COVID-19 diagnostics, therapeutics and vaccines

COMMITMENT and CALL TO ACTION

Our Vision and Mission

Grounded in a vision of a planet protected from human suffering and the devastating social and economic consequences of COVID-19, we, an initial group of global health actors (BMGF, CEPI, Gavi, Global Fund, UNITAID, Wellcome Trust, WHO) and private sector partners and other stakeholders, are launching a landmark, global and time-limited collaboration to accelerate the development, production and equitable global access to new COVID-19 essential health technologies.

We know that as long as anyone is at risk from this virus, the entire world is at risk – every single person on the planet needs to be protected from this disease.

We agree that alongside evidence-based public health measures, innovative COVID-19 diagnostics, therapeutics and vaccines are needed – in record time and at record scale and access – to save millions of lives and countless trillions of dollars, and to return the world to a sense of ‘normalcy’.

We recognize the significant amount of critical work, investment and initiatives already ongoing around the world to expedite the development and deployment of innovative COVID-19 related products and interventions.

We appreciate that while development and deployment of innovative products is essential, it will not be enough. We must simultaneously and urgently accelerate the strengthening of sustainable health systems and capacities to enable delivery of the new COVID-19 tools to those who need them and to mitigate the knock-on impact on other diseases.

We remember lessons from the past, which have shown that even when effective tools are available to the world, too often some are protected, while others are not. This inequity is unacceptable – all tools to address COVID-19 must be available to all. In the fight against COVID-19, no one should be left behind.

We understand we cannot do this alone, and that we need to work together in unprecedented and inclusive partnership with all stakeholders – political leaders, public and private sector partners, civil society, academia, and all other stakeholders across society – jointly leveraging our comparative strengths and respective voices to drive towards collective solutions, an accelerated path, and access for all. We are stronger, faster and more effective working together.

Our Mission is not only accelerated development and availability of new COVID-19 tools – it is to accelerate equitable global access to safe, quality, effective, and affordable COVID-19 diagnostics, therapeutics and vaccines, and thus to ensure that in the fight against COVID-19, no one is left behind.

Our Commitment

1. We commit to the shared aim of equitable global access to innovative tools for COVID-19 for all.
2. We commit to an unprecedented level of partnership – proactively engaging stakeholders, aligning and coordinating efforts, building on existing collaborations, collectively devising solutions, and grounding our partnership in transparency, and science.
3. We commit to create a strong unified voice to maximize impact, recognizing this is not about singular decision-making authority, but rather collective problem-solving, interconnectedness and inclusivity, where all stakeholders can connect and benefit from the expertise, knowledge and activities of this shared action-oriented platform.
4. We commit to build on past experiences towards achieving this objective, including ensuring that every activity we undertake is executed through the lens of equitable global access, and that the voices of the communities most affected are heard.
5. We commit to be accountable to the world, to communities, and to one another. We are coming together in the spirit of solidarity, and in the service of humanity, to achieve our mission and vision.

Our Call

We ask the global community and political leaders to support this landmark collaboration, and for donors to provide the necessary resources to accelerate achievement of the objectives of this global collaboration, capitalizing on the opportunity provided by the rolling pledging campaign that will start on 4 May 2020.

BILL & MELINDA
GATES foundation

dcvmn
Developing Countries Vaccine
Manufacturers Network

The Global Fund

IGBA
INTERNATIONAL GENERIC AND
BIOSIMILAR MEDICINES ASSOCIATION

W
wellcome

CEPI

Gavi
The Vaccine Alliance

IFPMA
International Federation
of Pharmaceutical
Manufacturers & Associations

Unitaid
Innovation in Global Health

World Health
Organization